Strategic Partnerships PHAR actively collaborates with major pharma players and trade associations, indicating openness to joint research and economic analyses. This suggests sales opportunities around health economics, outcomes research, and payer-focused studies with large partners.

Economic Modeling Recent collaborations with PhRMA and cost-effectiveness analyses point to demand for rigorous health economics and outcomes research methods. Target opportunities include economic models, budget impact analyses, and value dossiers for new and existing therapies.

Clinical Data Expertise PHAR combines clinical expertise with methodological rigor to address clinical and economic challenges. Opportunities exist to offer real-world evidence generation, observational studies, and claims-based analytics for treatment patterns and resource utilization.

Biotech and Oncology Focus Partnerships with oncology-related entities (e.g., Bristol Myers Squibb) and studies on CML and NMOSD indicate a strong foothold in oncology and neurology. Explore services around specialty pharma analytics, payer-grade evidence, and treatment pathway analyses.

Scale and Capability Revenue bracket and company size suggest capacity for mid-to-large scale projects and ongoing advisory engagements. Present scalable research programs, repeatable PMx/HEOR pipelines, and long-term consulting partnerships to sustain revenue growth.